Nasdaq · CIK 0001799788
GLSI Greenwich LifeSciences, Inc.
Insider trading from SEC Form 4. Last filing Jan 15, 2026. Close $16.53 on Oct 9, 2026, +111% from the 52-week low and -51% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
GLSIOct 9, 2026 · close 16.53
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Greenwich LifeSciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Snehal Patel CEO and CFO buy | $54k 1,800 shares | +0% | +270% from low0% from high | |
| 34Weak | Snehal Patel CEO and CFO buy | $80k 2,900 shares | +0% | +242% from low0% from high | |
| 38Weak | Snehal Patel CEO and CFO buy | $92k 4,300 shares | +0% | +168% from low-15% from high | |
| 33Weak | Snehal Patel CEO and CFO buy | $63k 2,900 shares | +0% | +179% from low-12% from high | |
| 32Weak | Snehal Patel CEO and CFO buy | $52k 4,100 shares | +0% | +58% from low-10% from high | |
| 49Moderate | Snehal Patel CEO and CFO buy | $39k 4,600 shares | +0% | +7% from low-44% from high | |
| 52Moderate | Snehal Patel CEO and CFO buy | $89k 10,600 shares | +0% | +7% from low-42% from high | |
| 38Weak | Snehal Patel CEO and CFO buy | $21k 2,300 shares | +0% | +5% from low-38% from high | |
| 39Weak | Snehal Patel CEO and CFO buy | $36k 3,600 shares | +0% | +13% from low-35% from high | |
| 50Moderate | Snehal Patel CEO and CFO buy | $48k 5,400 shares | +0% | +1% from low-41% from high | |
| 49Moderate | Snehal Patel CEO and CFO buy | $33k 3,600 shares | +0% | +9% from low-37% from high | |
| 50Moderate | Snehal Patel CEO and CFO buy | $48k 5,500 shares | +0% | 0% from low-42% from high | |
| 30Weak | Snehal Patel CEO and CFO buy | $31k 2,500 shares | +0% | - | |
| 31Weak | Snehal Patel CEO and CFO buy | $39k 2,900 shares | +0% | - | |
| 31Weak | Snehal Patel CEO and CFO buy | $44k 3,400 shares | +0% | - | |
| 25Weak | Snehal Patel CEO and CFO buy | $24k 2,000 shares | +0% | - | |
| 30Weak | Snehal Patel CEO and CFO buy | $27k 2,400 shares | +0% | - | |
| 26Weak | Snehal Patel CEO and CFO buy | $36k 3,200 shares | +0% | - | |
| 10Weak | Jaye Thompson VP Clinical Reg Affairs buy | $13k 1,000 shares | +0% | - |
Transactions
The last 28 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +1,800 | $29.83 | $54k | 5,604,102 | Jan 15, 2026 |
| Jan 12, 2026 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +2,900 | $27.54 | $80k | 5,602,302 | Jan 14, 2026 |
| Dec 31, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +4,300 | $21.36 | $92k | 5,599,402 | Jan 5, 2026 |
| Dec 30, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +2,900 | $21.73 | $63k | 5,595,102 | Jan 2, 2026 |
| Dec 18, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +4,100 | $12.62 | $52k | 5,592,202 | Dec 19, 2025 |
| Nov 25, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +4,600 | $8.37 | $39k | 5,588,102 | Nov 28, 2025 |
| Nov 13, 2025 | Snehal Patel CEO and CFO | AGrant or award Stock Optionsderivative | +100,000 | $0.00 | $0 | 2,347,462 | Nov 17, 2025 |
| Nov 7, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +10,600 | $8.43 | $89k | 5,583,502 | Nov 12, 2025 |
| Oct 31, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +2,300 | $9.26 | $21k | 5,572,902 | Nov 4, 2025 |
| Apr 25, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +3,600 | $9.88 | $36k | 5,570,602 | Apr 29, 2025 |
| Apr 17, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +5,400 | $8.98 | $48k | 5,567,002 | Apr 22, 2025 |
| Apr 7, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +3,600 | $9.10 | $33k | 5,561,602 | Apr 8, 2025 |
| Apr 4, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +5,500 | $8.73 | $48k | 5,558,002 | Apr 7, 2025 |
| Jan 10, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +2,500 | $12.51 | $31k | 5,552,502 | Jan 13, 2025 |
| Jan 6, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +1,100 | $13.31 | $15k | 5,548,202 | Jan 8, 2025 |
| Jan 7, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +1,800 | $13.75 | $25k | 5,550,002 | Jan 8, 2025 |
| Jan 3, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +3,400 | $12.95 | $44k | 5,547,102 | Jan 7, 2025 |
| Jan 2, 2025 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +2,000 | $11.97 | $24k | 5,543,702 | Jan 6, 2025 |
| Dec 31, 2024 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +2,400 | $11.36 | $27k | 5,541,702 | Jan 3, 2025 |
| Dec 30, 2024 | Snehal Patel CEO and CFO | POpen-market purchase Common Stock | +3,200 | $11.12 | $36k | 5,539,302 | Jan 2, 2025 |
| Dec 24, 2024 | Frank Joseph Daugherty Chief Medical Officer | AGrant or award Stock Optionsderivative | +104,890 | $0.00 | $0 | 209,780 | Dec 27, 2024 |
| Dec 24, 2024 | Eric Rothe director | AGrant or award Stock Optionsderivative | +41,349 | $0.00 | $0 | 82,698 | Dec 27, 2024 |
| Dec 24, 2024 | Kenneth Hallock director | AGrant or award Stock Optionsderivative | +41,349 | $0.00 | $0 | 82,698 | Dec 27, 2024 |
| Dec 24, 2024 | Jaye Thompson VP Clinical Reg Affairs | AGrant or award Stock Optionsderivative | +149,818 | $0.00 | $0 | 299,636 | Dec 27, 2024 |
| Dec 24, 2024 | David McWilliams director | AGrant or award Stock Optionsderivative | +61,984 | $0.00 | $0 | 123,968 | Dec 27, 2024 |
| Dec 24, 2024 | Snehal Patel CEO and CFO | AGrant or award Stock Optionsderivative | +1,148,723 | $0.00 | $0 | 2,222,454 | Dec 27, 2024 |
| Dec 24, 2024 | Snehal Patel CEO and CFO | AGrant or award Stock Optionsderivativeindirect: By Wife | +25,008 | $0.00 | $0 | 2,247,462 | Dec 27, 2024 |
| Nov 21, 2024 | Jaye Thompson VP Clinical Reg Affairs | POpen-market purchase Common Stock | +1,000 | $12.91 | $13k | 264,148 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Frank Joseph DaughertyChief Medical Officer
- Kenneth Hallockdirector
- David McWilliamsdirector
- Snehal PatelCEO and CFO
- Eric Rothedirector
- Jaye ThompsonVP Clinical Reg Affairs
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.